Cargando…
The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process
Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for thes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151305/ https://www.ncbi.nlm.nih.gov/pubmed/32244950 http://dx.doi.org/10.3390/pharmaceutics12030279 |
_version_ | 1783521219970072576 |
---|---|
author | Ervasti, Tuomas Niinikoski, Hannes Mäki-Lohiluoma, Eero Leppinen, Heidi Ketolainen, Jarkko Korhonen, Ossi Lakio, Satu |
author_facet | Ervasti, Tuomas Niinikoski, Hannes Mäki-Lohiluoma, Eero Leppinen, Heidi Ketolainen, Jarkko Korhonen, Ossi Lakio, Satu |
author_sort | Ervasti, Tuomas |
collection | PubMed |
description | Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for these challenges. Furthermore, the principle of a platform formulation was demonstrated for low dose tablets. The combination of filler excipients and the API in the formulation used was suitable for direct compression, but also prone to induce segregation in BDC process. The CDC process was found to be very promising; it was shown that tablets with the desired quality parameters could be manufactured successfully with both of the APIs studied. Powder analysis indicated that the APIs display some fundamental differences in their physical properties, which was also reflected in powder mixture properties and, hence, eventually in processing. However, process parameters, especially mixer impeller speed, were not found to have any significant influence on end product quality. The study suggests that a CDC process can be a viable solution to resolve the challenges described. Moreover, manufacturing by using a universal platform formulation seems to be a feasible way for producing low-dose tablets. |
format | Online Article Text |
id | pubmed-7151305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71513052020-04-20 The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process Ervasti, Tuomas Niinikoski, Hannes Mäki-Lohiluoma, Eero Leppinen, Heidi Ketolainen, Jarkko Korhonen, Ossi Lakio, Satu Pharmaceutics Article Segregation is a common problem in batch-based direct compression (BDC) processes, especially with low-dose tablet products, as is the preparation of a homogenous mixture. The scope of the current work was to explore if a continuous direct compression (CDC) process could serve as a solution for these challenges. Furthermore, the principle of a platform formulation was demonstrated for low dose tablets. The combination of filler excipients and the API in the formulation used was suitable for direct compression, but also prone to induce segregation in BDC process. The CDC process was found to be very promising; it was shown that tablets with the desired quality parameters could be manufactured successfully with both of the APIs studied. Powder analysis indicated that the APIs display some fundamental differences in their physical properties, which was also reflected in powder mixture properties and, hence, eventually in processing. However, process parameters, especially mixer impeller speed, were not found to have any significant influence on end product quality. The study suggests that a CDC process can be a viable solution to resolve the challenges described. Moreover, manufacturing by using a universal platform formulation seems to be a feasible way for producing low-dose tablets. MDPI 2020-03-20 /pmc/articles/PMC7151305/ /pubmed/32244950 http://dx.doi.org/10.3390/pharmaceutics12030279 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ervasti, Tuomas Niinikoski, Hannes Mäki-Lohiluoma, Eero Leppinen, Heidi Ketolainen, Jarkko Korhonen, Ossi Lakio, Satu The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title | The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title_full | The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title_fullStr | The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title_full_unstemmed | The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title_short | The Comparison of Two Challenging Low Dose APIs in a Continuous Direct Compression Process |
title_sort | comparison of two challenging low dose apis in a continuous direct compression process |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151305/ https://www.ncbi.nlm.nih.gov/pubmed/32244950 http://dx.doi.org/10.3390/pharmaceutics12030279 |
work_keys_str_mv | AT ervastituomas thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT niinikoskihannes thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT makilohiluomaeero thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT leppinenheidi thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT ketolainenjarkko thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT korhonenossi thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT lakiosatu thecomparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT ervastituomas comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT niinikoskihannes comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT makilohiluomaeero comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT leppinenheidi comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT ketolainenjarkko comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT korhonenossi comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess AT lakiosatu comparisonoftwochallenginglowdoseapisinacontinuousdirectcompressionprocess |